Here’s what you need to know.
1. For the year, Exact Sciences anticipates revenue between $99 million to 99.5 million, an increase of 150 percent from 2015.
2. The company said more than 9,500 providers ordered Cologuard for the first time during the fourth quarter; for the year, nearly 60,000 providers ordered the test — an 122 percent increase from 2015.
3. In June 2016, insurers covered 62 million more beneficiaries. As of Jan. 6, 2017, more than 163 million people are eligible to have their test covered.
4. Exact Sciences will report its complete figures during its February 2017 earnings call.
More articles on gastroenterology/endoscopy:
Dr. Steven Schwarz is American Academy of Pediatrics’ 2016 Murray Davidson Award recipient: 4 things to know
GI leader to know: Dr. Paul Warfield with ABQ Health Partners
Takeda, PvP Biologics to develop treatment for Celiac disease: 4 things to know
